Kymera Therapeutics, Inc. KYMR
Kymera Therapeutics, Inc. (Nasdaq: KYMR) is an immunology/inflammation drug developer. Its lead program, KT-621 (STAT6 degrader), is in Phase 2 for Atopic dermatitis (BROADEN2) and asthma (BREADTH).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| KT-621 (STAT6) | Atopic dermatitis (Phase 2b BROADEN2) | small molecule | Phase 2 |
| KT-621 (STAT6) | Asthma (Phase 2b BREADTH) | small molecule | Phase 2 |
| KT-579 (IRF5) | Autoimmune diseases (e.g. lupus, RA) | small molecule | Phase 1 |
| KT-485 / SAR447971 (IRAK4) | Inflammatory diseases | small molecule | Phase 1 |
| KT-200 (CDK2) | Oncology | small molecule | Pre-clinical |
Recent results and decisions
- Jun 25, 2026completed enrollment BROADEN2 Phase 2b enrollment (~200 patients ages 12-75) completed nearly six months ahead of timeline.
today announced it has completed enrollment in the global BROADEN2 Phase 2b trial of KT-621, its first-in-class, oral STAT6 degrader, for the treatment of moderate to severe atopic dermatitis (AD).
Filing - Apr 30, 2026n/a FDA granted Fast Track designation to KT-621 for moderate to severe eosinophilic asthma (April 2026).
In April 2026, the U.S. Food and Drug Administration granted Fast Track designation to KT-621 for the treatment of moderate to severe eosinophilic asthma.
Filing - Jan 13, 2026positive Recap of December 2025 BroADen Phase 1b: deep STAT6 degradation and biomarker/clinical improvements in line with or numerically exceeding dupilumab at 4 weeks, favorable safety.
In December 2025, the Company reported positive results from the KT-621 BroADen Phase 1b clinical trial in moderate to severe AD patients.
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.